Drug
Cnp 103
Cnp 103: highest development phase Phase 1/2, developed by COUR Pharmaceutical Development Company, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- COUR Pharmaceutical Development Company, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| CNP-103 NCT06783309 | Phase 1/2 | Type 1 Diabetes Mellitus |
Latest
No recent events.
Follow Cnp 103 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.